Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration

Autor: Teresa Di Desidero, Maria Sole Sartini, Guido Bocci, Michele Figus, Elisa Agosta, Marco Nardi, Paola Orlandi, Stefano Lazzeri, Romano Danesi, Anna Fioravanti
Rok vydání: 2012
Předmět:
Oncology
Vascular Endothelial Growth Factor A
medicine.medical_specialty
growth /&/ development/pathology
Porphyrins
genetic structures
Bevacizumab
Pegaptanib
Angiogenesis Inhibitors
Drusen
Polymorphism
Single Nucleotide
Internal medicine
medicine
Humans
genetics
Polymorphism
Precision Medicine
administration /&/ dosage
Neovascularization
Genetic Association Studies
administration /&/ dosage
Blood Vessels
growth /&/ development/pathology
Complement Factor H
genetics
Genetic Association Studies
Humans
Individualized Medicine
Neovascularization
Pathologic
drug therapy/genetics/pathology
Photochemotherapy
Polymorphism
Single Nucleotide
Porphyrins
administration /&/ dosage
Vascular Endothelial Growth Factor A
genetics
Wet Macular Degeneration
drug therapy/genetics/pathology
Pharmacology
Neovascularization
Pathologic
business.industry
Verteporfin
Single Nucleotide
Macular degeneration
Individualized Medicine
medicine.disease
eye diseases
Choroidal neovascularization
Photochemotherapy
Factor H
Complement Factor H
Wet Macular Degeneration
Molecular Medicine
Blood Vessels
sense organs
Ranibizumab
medicine.symptom
business
medicine.drug
Zdroj: Pharmacogenomics. 13(9)
ISSN: 1744-8042
Popis: Age-related macular degeneration (AMD), the most common age-related disease causing irreversible visual loss in industrialized countries, is a complex and multifactorial illness. Researchers have found components of the complement alternative pathway inside drusen and Bruch’s membrane of AMD patients, underlying a possible important role of complement factor H in the pathogenesis of AMD. The neovascular (wet) AMD is the most destructive form and it is characterized by invasion of new blood vessels into subretinal spaces with subsequent exudation and bleeding, resulting in scarring of the macular region and loss of the central vision. The hallmark of the neovascular form is the choroidal neovascularization, where VEGF-A has an important role in the pathogenesis of the disease. SNPs of these genes have recently been investigated as potential pharmacogenetic markers of the antiangiogenic and antineovascular therapy of AMD, which includes verteporfin photodynamic therapy and anti-VEGF-A drugs, such as pegaptanib, bevacizumab and ranibizumab. The CFH rs1061170 CT and TT genotypes have been associated with an improvement of visual acuity in bevacizumab or ranibizumab treated patients, whereas patients harboring VEGF-A rs699946 G allele responded better to bevacizumab-based therapy if compared with patients carrying the A allele. In conclusion, the discovery of pharmacogenetic markers for the personalization of the antiangiogenic and/or antineovascular therapy could be, in the future, a key issue in ophthalmology to obtain a personalization of the therapy and to avoid unnecessary costs and adverse drug reactions.
Databáze: OpenAIRE
Externí odkaz: